APR. 8. 2004 9:03AM AVENTIS US PAT DEPT T≒O: US USPTO GENERAL

NO. 1321 PRÉCEIVED
CENTRAL FAX CENTER

			APIALLIVIE	
	ANSMITTAL	• .	APR 0	8 (
TO THE UNITED ST	TATES PATENT	OFFICE		
				A d
				Ш
Applicants Docket Number:				Ø,
DEAV2001/0073 US NP	CERTIFICATE OF TRANSMISSION			
•	I hereby certify that this correspondence is being transmitted via			
Applicants:	facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 703-872-9306, on			
WEITHMANN, et al.	Date of Deposit April 8, 2004			
·		Signing Certificate Paul Tr	vine	
0. 1.131		000 =		
Serial No.	Signature			
10/065, 944				
10/065, 994	Total Num	ber of Pages Sent:	3	
Filing Date:	Attorney:	George G. Wang		
12/09/2002		0-11g- 0-11-mg	1	
	Group Art Unit:	1624		
Tide of Invention:	Examiner:	Habte, Kahsay	ľ	
PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES		E-4.6-DICAPROXVI	TC ACM	
DIAMIDES AND THE USE THEREOF FOR SELECT	TIVELY INHIBITI	NG COLLAGENASE	S S	
		in Compagnitude	~	
To:	IIVELY INHIBITI	NG COLLAGENASE	:S 	
Commissioner for Patents				

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

	Amendment, 37 CFR		Fee Transmittal
	Charge deposit account, in duplicate		Petition under 37 CFR
	Extension of Time Petition	\boxtimes	Other Reply to Office Action
	Issue Fee Transmittal & Advance Order		Other
П	Maintenance Fee Transmittal		

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this tolecopy transmission are intended only for the use of the individual or entity aemed above. If you have received this reference in the return of the original documents.

Avends Pharmaceuticals Inc. template (March 2001)

P. O. Box 1450

Alexandría, VA 22313-1450